ERBB2 and breast cancer: In a retrospective series of 86 breast cancer patients treated with neoadjuvant fluorouracil, epirubicin and cyclophosphamide (FEC), we evaluated response, time to progression (TTP) and overall survival (OS) according to the simplified classification of breast cancer subtypes based on ER, PR and HER2.